Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Concurrent Epirubicin/Taxane in Node-Positive Breast Cancer
NCT00140075Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2000
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Disease Free Survival at 3 years. Started Nov 2000; status: completed.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00140075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140075.